Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting held in Houston, TX, Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, gives us an update on the exciting trial of asciminib plus imatinib for chronic myeloid leukemia (CML) patients in the chronic phase (NCT03578367). Asciminib is a promising new TKI, which Dr Saglio refers to as a 'fourth generation' TKI, as he explains its mechanism of action.
